Kelsey D R, Flanagan T D, Young J E, Yeagle P L
Department of Biochemistry, School of Medicine and Biomedical Sciences, State University of New York, Buffalo 14214.
Virology. 1991 Jun;182(2):690-702. doi: 10.1016/0042-6822(91)90610-n.
Hydrophobic di- and tripeptides which are capable of inhibiting enveloped virus infection of cells are also capable of inhibiting at least three different types of membrane fusion events. Large unilamellar vesicles (LUV) of N-methyl dioleoylphosphatidylethanolamine (N-methyl DOPE), containing encapsulated 1-aminonaphthalene-3,6,8-trisulfonic acid (ANTS) and/or p-xylene bis(pyridinium bromide) (DPX), were formed by extrusion. Vesicle fusion (contents mixing) and leakage were then monitored with the ANTS/DPX fluorescence assay. Sendai virus fusion with lipid vesicles and Sendai virus fusion with human erythrocyte membranes were measured by following the relief of fluorescence quenching of virus labeled with octadecylrhodamine B chloride (R18), a lipid mixing assay for fusion. This study found that the effectiveness of the peptides carbobenzoxy-L-Phe-L-Phe (Z-L-Phe-L-Phe), Z-L-Phe, Z-D-Phe, and Z-Gly-L-Phe-L-Phe in inhibiting N-methyl DOPE LUV fusion or fusion of virus with N-methyl DOPE LUV also paralleled their reported ability to block viral infectivity. Furthermore, Z-D-Phe-L-PheGly and Z-Gly-L-Phe inhibited Sendai virus fusion with human erythrocyte membranes with the same relative potency with which they inhibited vesicle-vesicle and virus-vesicle fusion. The evidence suggests a mechanism by which these peptides exert their inhibition of plaque formation by enveloped viruses. This class of inhibitors apparently acts by inhibiting fusion of the viral envelope with the target cell membrane, thereby preventing viral infection. The physical pathway by which these peptides inhibit membrane fusion was investigated. 31P nuclear magnetic resonance (NMR) of proposed intermediates in the pathway for membrane fusion in LUV revealed that the potent fusion inhibitor Z-D-Phe-L-PheGly selectively altered the structure (or dynamics) of the hypothesized fusion intermediates and that the poor inhibitor Z-Gly-L-Phe did not. One possible interpretation of these 31P NMR results was that the inhibitory peptide stabilized a membrane structure with a large radius of curvature, when the fusion pathway demanded a membrane defect with a small radius of curvature. This hypothesis was tested by determining the influence of an inhibitory and a noninhibitory peptide on the formation of membraneous structures with small radii of curvature, through ultrasonic irradiation of phospholipid dispersions. The inhibitory peptide prevented the formation of membrane structures with small radii of curvature, while the noninhibitory peptide did not prevent the formation of such structures.(ABSTRACT TRUNCATED AT 400 WORDS)
能够抑制包膜病毒感染细胞的疏水性二肽和三肽,也能够抑制至少三种不同类型的膜融合事件。通过挤压形成了含有包封的1-氨基萘-3,6,8-三磺酸(ANTS)和/或对二甲苯双(溴化吡啶)(DPX)的N-甲基二油酰磷脂酰乙醇胺(N-甲基DOPE)的大单层囊泡(LUV)。然后用ANTS/DPX荧光测定法监测囊泡融合(内容物混合)和渗漏情况。通过跟踪用十八烷基罗丹明B氯化物(R18)标记的病毒荧光猝灭的解除情况,测定仙台病毒与脂质囊泡的融合以及仙台病毒与人红细胞膜的融合,这是一种用于融合的脂质混合测定法。本研究发现,苄氧羰基-L-苯丙氨酸-L-苯丙氨酸(Z-L-Phe-L-Phe)、Z-L-苯丙氨酸、Z-D-苯丙氨酸和Z-甘氨酸-L-苯丙氨酸-L-苯丙氨酸在抑制N-甲基DOPE LUV融合或病毒与N-甲基DOPE LUV融合方面的有效性,也与其报道的阻断病毒感染性的能力平行。此外,Z-D-苯丙氨酸-L-苯丙氨酸-甘氨酸和Z-甘氨酸-L-苯丙氨酸以与它们抑制囊泡-囊泡和病毒-囊泡融合相同的相对效力,抑制仙台病毒与人红细胞膜的融合。证据表明了这些肽抑制包膜病毒形成蚀斑的一种机制。这类抑制剂显然是通过抑制病毒包膜与靶细胞膜的融合来发挥作用的,从而防止病毒感染。研究了这些肽抑制膜融合的物理途径。对LUV膜融合途径中假定中间体的31P核磁共振(NMR)研究表明,有效的融合抑制剂Z-D-苯丙氨酸-L-苯丙氨酸-甘氨酸选择性地改变了假定融合中间体的结构(或动力学),而效果较差的抑制剂Z-甘氨酸-L-苯丙氨酸则没有。对这些31P NMR结果的一种可能解释是,当融合途径需要一个小曲率半径的膜缺陷时,抑制性肽稳定了一个大曲率半径的膜结构。通过对磷脂分散体进行超声辐照,测定抑制性和非抑制性肽对小曲率半径膜结构形成的影响,对这一假设进行了检验。抑制性肽阻止了小曲率半径膜结构的形成,而非抑制性肽则没有阻止此类结构的形成。(摘要截断于400字)